Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

NCT01348490 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

MPN (Myeloproliferative Neoplasms)

Interventions

DRUG: Ruxolitinib

Sponsor

Incyte Corporation